TW202302095A - 使用ｂｅｔ抑制劑治療骨髓纖維化 - Google Patents

使用ｂｅｔ抑制劑治療骨髓纖維化 Download PDF

Info

Publication number
TW202302095A
TW202302095A TW111107087A TW111107087A TW202302095A TW 202302095 A TW202302095 A TW 202302095A TW 111107087 A TW111107087 A TW 111107087A TW 111107087 A TW111107087 A TW 111107087A TW 202302095 A TW202302095 A TW 202302095A
Authority
TW
Taiwan
Prior art keywords
pharmaceutically acceptable
compound
acceptable salt
formula
aspects
Prior art date
Application number
TW111107087A
Other languages
English (en)
Chinese (zh)
Inventor
伊達 艾若齊克
凡倫西亞 蕊克夏納 凡樂瑞亞 貝特芮恩
安東 瑪麗亞 索拉雅 卡倫西歐
曾慶豐
索戴迪 庫克
夏爾米拉 達斯
艾倫 霍普 菲法若夫
馬露恩達 卡拉 瓜瑞諾斯
比索伊 哈娜
劉宇
札瑞亞那 尼克洛法
歐瑞安納 艾斯波系多
Original Assignee
美商生物醫學影響公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 美商生物醫學影響公司 filed Critical 美商生物醫學影響公司
Publication of TW202302095A publication Critical patent/TW202302095A/zh

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Disintegrating Or Milling (AREA)
TW111107087A 2021-02-25 2022-02-25 使用ｂｅｔ抑制劑治療骨髓纖維化 TW202302095A (zh)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
EP21382163.0 2021-02-25
EP21382163 2021-02-25
US202163232866P 2021-08-13 2021-08-13
US63/232,866 2021-08-13
US202263297098P 2022-01-06 2022-01-06
US63/297,098 2022-01-06

Publications (1)

Publication Number Publication Date
TW202302095A true TW202302095A (zh) 2023-01-16

Family

ID=80786345

Family Applications (1)

Application Number Title Priority Date Filing Date
TW111107087A TW202302095A (zh) 2021-02-25 2022-02-25 使用ｂｅｔ抑制劑治療骨髓纖維化

Country Status (12)

Country Link
US (2) US12357621B2 (https=)
EP (1) EP4297750A1 (https=)
JP (1) JP2024507938A (https=)
KR (1) KR20230148208A (https=)
AU (1) AU2022227673A1 (https=)
CA (1) CA3206708A1 (https=)
CL (1) CL2023002497A1 (https=)
IL (1) IL304697A (https=)
MX (1) MX2023009858A (https=)
TW (1) TW202302095A (https=)
WO (1) WO2022182857A1 (https=)
ZA (1) ZA202307538B (https=)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022261204A1 (en) 2021-06-08 2022-12-15 The Regents Of The University Of California Anticancer compounds
TW202508595A (zh) 2023-05-04 2025-03-01 美商銳新醫藥公司 用於ｒａｓ相關疾病或病症之組合療法
US20250049810A1 (en) 2023-08-07 2025-02-13 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
AU2024360465A1 (en) 2023-10-12 2026-04-09 Revolution Medicines, Inc. Macrocyclic ras inhibitors
WO2025171296A1 (en) 2024-02-09 2025-08-14 Revolution Medicines, Inc. Ras inhibitors
TW202547461A (zh) 2024-05-17 2025-12-16 美商銳新醫藥公司 Ｒａｓ抑制劑
WO2025255438A1 (en) 2024-06-07 2025-12-11 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2025265060A1 (en) 2024-06-21 2025-12-26 Revolution Medicines, Inc. Therapeutic compositions and methods for managing treatment-related effects
WO2026006747A1 (en) 2024-06-28 2026-01-02 Revolution Medicines, Inc. Ras inhibitors
WO2026015790A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015801A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015796A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015825A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Use of ras inhibitor for treating pancreatic cancer
WO2026050446A1 (en) 2024-08-29 2026-03-05 Revolution Medicines, Inc. Ras inhibitors
WO2026072904A2 (en) 2024-09-26 2026-04-02 Revolution Medicines, Inc. Compositions and methods for treating lung cancer

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5191391B2 (ja) 2005-11-01 2013-05-08 ターゲジェン インコーポレーティッド キナーゼのビ−アリールメタ−ピリミジン阻害剤
SG10202003901UA (en) 2005-12-13 2020-05-28 Incyte Holdings Corp Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as janus kinase inhibitors
KR20150036210A (ko) 2007-06-13 2015-04-07 인사이트 코포레이션 야누스 키나제 억제제（Ｒ）―３―（４―（７Ｈ―피롤로［２，３－ｄ］피리미딘―4―일）―1Ｈ―피라졸―1―일）―３―사이클로펜틸프로판니트릴의 염
AU2010363329A1 (en) 2010-11-07 2013-05-09 Targegen, Inc. Compositions and methods for treating myelofibrosis
KR102457145B1 (ko) * 2013-12-24 2022-10-19 브리스톨-마이어스 스큅 컴퍼니 항암제로서의 트리시클릭 화합물
US9458156B2 (en) 2014-12-23 2016-10-04 Bristol-Myers Squibb Company Tricyclic compounds as anticancer agents
EP3355922A2 (en) * 2015-10-02 2018-08-08 Dana Farber Cancer Institute, Inc. Combination therapy of bromodomain inhibitors and checkpoint blockade
US12391676B2 (en) * 2018-09-07 2025-08-19 H. Lee Moffitt Cancer Center And Research Institute, Inc. BRD4-JAK2 inhibitors
BR112021005518A2 (pt) 2018-09-25 2021-06-29 Impact Biomedicines, Inc. métodos para tratar distúrbios mieloproliferativos
FI3908281T3 (fi) * 2019-01-09 2024-10-01 Celgene Corp Antiproliferatiivisia yhdisteitä ja toisia aktiivisia aineita käytettäväksi multippelin myelooman hoidossa
US12559463B2 (en) 2019-02-12 2026-02-24 Impact Biomedicines Inc. Crystalline forms of a JAK2 inhibitor
PT4161528T (pt) * 2020-06-03 2026-01-23 Incyte Corp Combinação de ruxolitinib com incb057643 para utilização no tratamento de neoplasias mieloproliferativas

Also Published As

Publication number Publication date
IL304697A (en) 2023-09-01
US12357621B2 (en) 2025-07-15
CA3206708A1 (en) 2022-09-01
WO2022182857A1 (en) 2022-09-01
AU2022227673A9 (en) 2024-09-19
EP4297750A1 (en) 2024-01-03
ZA202307538B (en) 2026-01-28
US20220265617A1 (en) 2022-08-25
US20250367174A1 (en) 2025-12-04
AU2022227673A1 (en) 2023-08-17
CL2023002497A1 (es) 2024-01-12
MX2023009858A (es) 2023-09-12
KR20230148208A (ko) 2023-10-24
JP2024507938A (ja) 2024-02-21

Similar Documents

Publication Publication Date Title
TW202302095A (zh) 使用ｂｅｔ抑制劑治療骨髓纖維化
JP2023515817A (ja) ダブラフェニブ、ｅｒｋ阻害剤及びｓｈｐ２阻害剤を含む三重の医薬品の組合せ
JP6090836B2 (ja) 化学療法剤の抗腫瘍活性増強剤
JP2024012493A (ja) 消化管間質腫瘍の治療のための併用療法
US20090312290A1 (en) Combination of a nitrogen mustard analogue and imatinib for treatment of chronic lymphocytic leukemia
RU2494736C2 (ru) Комбинация, включающая паклитаксел, для лечения рака яичников
CN113274392A (zh) 用于治疗慢性咳嗽的奥维匹坦
US10576050B2 (en) Methods and compositions for treatment of cancer
TW200808313A (en) Compositions and methods for treating rheumatoid arthritis
US9018176B2 (en) Inducers of hematopoiesis and fetal globin production for treatment of cytopenias and hemoglobin disorders
JP2011507880A (ja) 慢性リンパ性白血病の処置のためのニロチニブとナイトロジェンマスタードの組み合わせ剤
KR20220124739A (ko) 암의 치료를 위한 병용 요법
EA050366B1 (ru) Применение ингибиторов bet отдельно или в комбинации с федратинибом или с руксолитинибом для лечения гематологического злокачественного новообразования, такого как миелофиброз
CN117615759A (zh) Bet抑制剂单独或者与菲卓替尼或芦可替尼组合用于治疗血液恶性肿瘤如骨髓纤维化的用途
WO2023011488A1 (zh) 一种药物组合及其用途
CN117177752A (zh) 用于治疗mpnst的化合物和组合物
EP2298309B1 (en) Antitumor agent, kit and method of treating cancer
US20080312250A1 (en) Combination Comprising a Bcrp Inhibitor and 4- (4-Methylpiperazin-1-Ylmethyl)-N-[4-Methyl-3- (4-Pyridin-3-Yl) Pyrimidin-2-Ylamino) Phenyl] -Benzamide
US20090176759A1 (en) Leukemic stem cell ablation
WO2025078276A1 (en) Combination of a parp-1 selective inhibitor and temozolimde and its use in the treatment of glioma
WO2025056055A1 (zh) 新一代egfr抑制剂单药或联合使用在制备肿瘤疾病的药物中的应用
WO2025214358A1 (zh) 用于治疗胰腺癌的药物及其用途
WO2007010014A2 (en) Compositions for treatment of systemic mastocytosis
WO2018074409A1 (ja) 慢性骨髄性白血病を治療又は寛解するための医薬組成物
HK1256017A1 (en) Therapeutic combinations of orally administered paclitaxel and a p-gp inhibitor for the treatment of cancer